UBR2 expression based on
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Comparison | Statistical significance |
Normal-vs-Primary | 2.84040013731612E-10 |
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Stage1 |
1.008490E-04 |
Normal-vs-Stage2 |
5.97959999999453E-05 |
Normal-vs-Stage3 |
N/A |
Normal-vs-Stage4 |
4.362500E-03 |
Stage1-vs-Stage2 |
3.481800E-01 |
Stage1-vs-Stage3 |
N/A |
Stage1-vs-Stage4 |
6.988400E-01 |
Stage2-vs-Stage3 |
N/A |
Stage2-vs-Stage4 |
6.008200E-01 |
Stage3-vs-Stage4 |
N/A |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Caucasian |
4.21510004677828E-09 |
Normal-vs-AfricanAmerican |
2.409800E-01 |
Normal-vs-Asian |
1.9722799999955E-05 |
Caucasian-vs-AfricanAmerican |
4.054100E-02 |
Caucasian-vs-Asian |
7.820400E-01 |
AfricanAmerican-vs-Asian |
1.533050E-01 |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Male |
6.02789999999409E-05 |
Normal-vs-Female |
6.23589999970697E-07 |
Male-vs-Female |
2.382800E-01 |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Patient BMI information is not available for 1 sample.
Descriptions |
Normal weight |
BMI greater than equal to 18.5 and BMI less than 25 |
Extereme weight |
BMI greater than equal to 25 and BMI less than 30 |
Obese |
BMI greater than equal to 30 and BMI less than 40 |
Extreme Obese |
BMI greater than 40 |
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Normal_Weight |
1.657500E-03 |
Normal-vs-Extreme_Weight |
1.202540E-04 |
Normal-vs-Obese |
1.778690E-03 |
Normal-vs-Extreme_Obese |
N/A |
Normal_Weight-vs-Extreme_Weight |
9.003200E-01 |
Normal_Weight-vs-Obese |
1.075040E-01 |
Normal_Weight-vs-Extreme_Obese |
N/A |
Extreme_Weight-vs-Obese |
1.021760E-01 |
Extreme_Weight-vs-Extreme_Obese |
N/A |
Obese-vs-Extreme_Obese |
N/A |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Age(21-40Yrs) |
1.181600E-01 |
Normal-vs-Age(41-60Yrs) |
2.799100E-03 |
Normal-vs-Age(61-80Yrs) |
4.4396999998586E-07 |
Normal-vs-Age(81-100Yrs) |
3.54060000000711E-05 |
Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.226560E-01 |
Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.512100E-02 |
Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.764970E-01 |
Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.363200E-01 |
Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.826000E-01 |
Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.331800E-01 |
|
|
CHOL : Cholangiocarcinoma
Subtype descriptions |
Grade 1 | Well differentiated (low grade) |
Grade 2 | Moderately differentiated (intermediate grade) |
Grade 3 | Poorly differentiated (high grade) |
Grade 4 | Undifferentiated (high grade) |
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Grade 1 |
N/A |
Normal-vs-Grade 2 |
7.510000E-01 |
Normal-vs-Grade 3 |
9.235000E-01 |
Normal-vs-Grade 4 |
1.000000E+00 |
Grade 1-vs-Grade 2 |
N/A |
Grade 1-vs-Grade 3 |
N/A |
Grade 1-vs-Grade 4 |
N/A |
Grade 2-vs-Grade 3 |
6.029400E-01 |
Grade 2-vs-Grade 4 |
7.510000E-01 |
Grade 3-vs-Grade 4 |
9.235000E-01 |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 5 samples.
pathologic_N descriptions |
N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-N0 |
1.57729999950007E-07 |
Normal-vs-N1 |
1.715760E-02 |
N0-vs-N1 |
5.885200E-01 |
|
|